| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYH3 |
| Uniprot No | P11055 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-100aa |
| 氨基酸序列 | SSDTEMEVFGIAAPFLRKSEKERIEAQNQPFDAKTYCFVVDSKEEYAKGK IKSSQDGKVTVETEDNRTLVVKPEDVYAMNPPKFDRIEDMAMLTHLNEP |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYH3重组蛋白的3篇参考文献及其摘要概括(文献为虚拟示例，供参考)：
---
1. **文献名称**：Functional Analysis of Recombinant MYH3 in Embryonic Muscle Development
**作者**：Smith, J. et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化MYH3重组蛋白，证实其在胚胎期肌管形成中的关键作用。通过体外实验发现，MYH3缺陷导致肌细胞融合异常，提示其与先天性肌病相关。
2. **文献名称**：Structural Characterization of MYH3 Mutants via Recombinant Protein Expression
**作者**：Li, X. et al.
**摘要**：利用昆虫细胞系统表达携带致病突变的MYH3重组蛋白，结合冷冻电镜解析结构，揭示特定突变(如R672C)干扰肌球蛋白ATP酶活性，为关节弯曲症提供分子机制依据。
3. **文献名称**：High-Yield Production of MYH3 in Mammalian Cells for Therapeutic Screening
**作者**：Garcia, R. et al.
**摘要**：开发HEK293细胞系高效分泌MYH3重组蛋白的方法，应用于药物筛选平台，成功鉴定出可恢复突变型MYH3功能的小分子化合物，推动潜在疗法开发。
---
*注：以上文献为模拟内容，实际研究中建议通过PubMed/Google Scholar以“MYH3 recombinant protein”、“MYH3 expression”等关键词检索最新论文。*
MYH3. encoding myosin heavy chain 3. is a sarcomeric protein critical for skeletal muscle development and contractile function. As part of the myosin superfamily, MYH3 forms the motor subunit of myosin II, interacting with actin filaments to generate mechanical force during muscle contraction. Structurally, the MYH3 protein consists of an N-terminal motor domain (ATPase activity), a helical neck region bound to light chains, and a C-terminal tail involved in dimerization. During embryogenesis, MYH3 is predominantly expressed in developing skeletal muscles and plays a key role in myoblast fusion, sarcomere assembly, and fetal movement. Its temporal expression peaks in the second trimester, making it a vital biomarker for studying neuromuscular development.
Mutations in MYH3 are linked to congenital contractural syndromes, notably Freeman-Sheldon syndrome and distal arthrogryposis, characterized by joint rigidity, muscle weakness, and craniofacial abnormalities. These pathogenic variants often disrupt myosin's ATPase activity or actin-binding capacity, impairing sarcomere function. Recombinant MYH3 protein, typically produced in bacterial or mammalian expression systems with affinity tags (e.g., His-tag), enables functional studies of these mutations. Researchers use it to analyze structural impacts, measure ATP hydrolysis kinetics, and screen therapeutic compounds. Purification involves chromatography techniques like nickel-affinity or size-exclusion, with quality validation via SDS-PAGE, Western blot, and circular dichroism.
Current applications include disease modeling using CRISPR-edited cell lines, drug discovery for motility disorders, and structural biology studies using cryo-EM to resolve mutant myosin conformations. Challenges remain in maintaining protein stability due to MYH3's large size (~224 kDa) and post-translational modifications in eukaryotic systems. Ongoing research explores its role in adult muscle regeneration and potential therapeutic targeting for congenital myopathies.
×
